CARLSBAD, Calif., July 2, 2026
Arima Genomics, Inc. announced an exclusive distribution partnership with Active Motif Incorporated, granting the life sciences company exclusive rights to distribute Arima’s Hi-C sequencing kits and research services for research applications worldwide. The agreement covers Arima’s complete portfolio of 3D genomics research products for non-formalin fixed paraffin embedded (non-FFPE) sample types, including cell lines, blood samples, and fresh-frozen tissues. The collaboration is designed to ensure continued availability of Arima’s advanced Hi-C technologies to the global research community while allowing the company to sharpen its focus on developing its clinical cancer diagnostics platform. By leveraging Active Motif’s established commercial network and expertise in epigenetics and multiomics, researchers will continue to gain access to powerful genomic tools used to study gene regulation, chromatin architecture, disease biology, and functional genomics.
Strategic Partnership Supports Arima’s Clinical Diagnostics Expansion
The distribution agreement represents an important component of Arima Genomics’ long-term corporate strategy to concentrate resources on its growing portfolio of clinical diagnostic tests. The company plans to prioritize development and commercialization of its proprietary Aventa clinical testing platform, which utilizes Hi-C sequencing technology to analyze the three-dimensional organization of cancer genomes from routine FFPE tissue samples. Unlike conventional sequencing approaches that primarily examine DNA sequence alone, Arima’s platform combines DNA sequence and structural genomic information to identify clinically relevant genomic rearrangements that may otherwise remain undetected. Current commercial offerings include Aventa FusionPlus for solid tumors and Aventa Lymphoma, both designed to detect actionable gene fusions and structural alterations that can influence cancer diagnosis, treatment selection, and personalized patient care. Company leadership stated that partnering with Active Motif allows Arima to maintain strong support for the research community while dedicating greater investment toward expanding its clinical diagnostics business.
Hi-C Technology Enables Advanced Genomics and Disease Research
Arima’s Hi-C sequencing platform has become an important technology for scientists studying the three-dimensional organization of the genome and its influence on biological function. The research products included in the agreement support a broad range of applications, including epigenetics, gene regulation, human disease research, reference-quality genome assembly, and haplotype phasing. These capabilities enable researchers to better understand chromosome interactions, regulatory networks, and structural genomic variations that contribute to cancer and other diseases. Through its expertise in epigenomics and multiomics, Active Motif is well positioned to integrate Arima’s Hi-C technologies into its existing portfolio, providing customers with expanded access to advanced genomic research solutions while supporting innovation across mechanistic, translational, and clinical research programs worldwide.
Advertisement
Collaboration Strengthens Precision Oncology and Genomics Innovation
The partnership reinforces Arima Genomics’ commitment to advancing precision oncology through innovative genomic technologies while establishing Active Motif as the exclusive commercial partner for its research-focused Hi-C products. Company executives emphasized that integrating DNA sequence with three-dimensional genome structure offers a more comprehensive understanding of cancer biology and has the potential to improve identification of disease-driving genomic alterations. Industry leaders also noted that the agreement positions Arima to accelerate development of next-generation cancer diagnostics while allowing Active Motif to broaden its portfolio of cutting-edge genomic research tools. As demand continues to grow for multiomic and structural genomics technologies, the collaboration is expected to support both scientific discovery and the development of more precise diagnostic solutions that can ultimately improve patient outcomes in oncology and other complex diseases.
Source: Arima Genomics press release
